Iovance Biotherapeutics Shares Surge on Positive Clinical Trial Data
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 24 2026
0mins
Should l Buy IOVA?
Source: Benzinga
- Clinical Trial Results: Iovance Biotherapeutics reported a 50% confirmed objective response rate (ORR) in a pilot trial for its TIL cell therapy among six evaluable patients, establishing a strong foundation for market opportunities in soft tissue sarcomas.
- Market Potential: With over 8,000 patients diagnosed annually in the U.S. and Europe with advanced undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma, Iovance's therapy is poised to address significant unmet medical needs, potentially driving future growth.
- Future Plans: The company intends to commence a single-arm registrational trial in Q2 2026 and engage with the FDA for expedited approval, demonstrating its proactive approach and confidence in the new therapy's potential.
- Stock Performance: Following the announcement, Iovance's shares surged by 29.41% to $3.74, reflecting strong investor enthusiasm for its clinical advancements, while aligning with the broader positive market trend.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IOVA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IOVA
Wall Street analysts forecast IOVA stock price to rise
8 Analyst Rating
6 Buy
1 Hold
1 Sell
Moderate Buy
Current: 3.510
Low
1.50
Averages
9.50
High
17.00
Current: 3.510
Low
1.50
Averages
9.50
High
17.00
About IOVA
Iovance Biotherapeutics, Inc. is a commercial biotechnology company. The Company is focused on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Its products include Amtagvi and Proleukin. Amtagvi is indicated for the treatment of adult patients with melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor, with or without a MEK inhibitor. It is marketing Proleukin (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi treatment regimen and in other applications. Amtagvi and Proleukin are part of a treatment regimen that includes lymphodepletion. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings and indications for solid tumor cancers. Its TIL therapy includes melanoma, non-small cell lung cancer and gynecologic cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Avaí Bio Initiates Key Cell Bank Project for Therapy Development
- Market Outlook: The regenerative medicine market is projected to reach $578 billion by 2026, with cell therapy alone surpassing $8.2 billion this year, indicating strong growth potential that attracts investor interest.
- Infrastructure Development: Avaí Bio has initiated the creation of a Master Cell Bank (MCB) for the α-Klotho protein in collaboration with Austrianova, ensuring a standardized foundation for future cell therapies, enhancing the feasibility and consistency of product development.
- Scientific Research Support: The α-Klotho protein is extensively studied and linked to reduced risks of Alzheimer's, cardiovascular diseases, and certain cancers, with a significant market potential, as the Alzheimer's market is expected to reach $32.8 billion by 2033.
- Dual-Program Strategy: Avaí Bio's Insulinova platform also utilizes Cell-in-a-Box® technology to target diabetes, showcasing the company's diversified approach in the cell therapy field, thereby enhancing its competitive position in the market.
See More
Avaí Bio Initiates Key Cell Bank Project for Therapy Development
- Market Potential: The regenerative medicine market is projected to reach $578 billion by 2033, with cell therapy alone surpassing $8.2 billion in 2026, indicating a rapid growth trajectory that is attracting significant investment and research resources.
- Infrastructure Importance: Avaí Bio has initiated a Master Cell Bank (MCB) project in collaboration with Austrianova to create a standardized cellular starting material by cloning a single genetically engineered cell into tens of millions of identical copies, ensuring consistency and scalability for future therapy development.
- Clinical Application Outlook: The α-Klotho protein is linked to various age-related diseases, with the Alzheimer's market expected to reach $32.8 billion by 2033, positioning Avaí Bio's research to potentially achieve groundbreaking advancements in these critical health areas.
- Technological Innovation and Market Competitiveness: Avaí Bio's Insulinova platform also leverages Cell-in-a-Box® technology to address diabetes by protecting therapeutic cells, showcasing the company's innovative capabilities and competitive edge in the cell therapy landscape.
See More
How Two Small Biotech Companies Could Pave the Way for Innovative Cancer Therapies
Cancer as a Medical Challenge: Cancer remains a significant challenge for biotechnology firms, with the oncology market projected to surge to $366 billion in the next 80 years, prompting companies to develop targeted treatments for specific cancer types.
Promising Treatments and Market Growth: Several promising cancer treatments have shown incredible potential, leading to significant sales opportunities for biotech firms, particularly those focusing on oncology medicines.
Iovance's Market Performance: Iovance Biotherapeutics has experienced substantial share price growth, driven by its leading cancer drug, which has the potential to generate over $1 billion in U.S. sales, despite facing production challenges.
Immunity Bio's Growth and Challenges: Immunity Bio has seen impressive sales growth for its bladder cancer drug, Anktiva, following regulatory approvals, but it still faces risks and challenges in manufacturing and market competition.
See More
ImmunityBio and Iovance Stock Dynamics Analysis
- Stock Performance Comparison: IBRX's stock has fallen over 7% this week, dropping to $9 on Wednesday, while IOVA's stock has gained nearly 11%, reaching $4.26 on the same day, indicating differing market sentiments that could influence investor decisions.
- Sales Revenue Growth: ImmunityBio generated $113 million in revenue from Anktiva in 2025, up approximately 700% year-over-year, while Iovance reported about $87 million in Q4, exceeding estimates of $81.01 million, demonstrating strong market demand for both companies' therapies.
- Analyst Outlook Assessment: Analyst estimates from Koyfin suggest ImmunityBio has price targets ranging from $9 to $23, with an average target of $14.75 implying a 64% upside from current levels, while Iovance's targets range from $2 to $16, averaging $8.8, indicating a potential 107% upside, reflecting differing market expectations for both firms.
- Clinical Trial Progress: ImmunityBio's Quilt 2.005 trial shows that 85% of patients maintained a complete response at six months with Anktiva and BCG combination therapy, while Iovance's trial in new tumor types shows a 50% response rate, indicating positive advancements in expanding market potential for both companies.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting varying market perspectives and future expectations for these firms.
- ORCL Stock Outlook: Analysts have provided their latest views on ORCL stock for potential buyers, which could influence investor decisions and market sentiment regarding the stock.
- Market Dynamics Overview: The backdrop for these rating changes is a shifting market environment, with analysts evaluating based on the latest financial data and industry trends, indicating a cautious outlook on the overall market.
- Investor Focus: Investors should pay attention to these rating changes as they may impact stock price volatility and investment strategies for the affected companies, particularly in an uncertain economic climate.
See More
Iovance Biotherapeutics Reports Record Q4 Margins and Strong Upside Potential
- Record Quarterly Profit: Iovance reported Q4 revenue of $86.7 million, exceeding analyst expectations of $81 million, with gross margins rising from 43% in Q3 to 50%, demonstrating the effectiveness of operational optimization and indicating potential for future profitability improvements.
- Sales Growth: Total product revenue for Q4 reached approximately $87 million, a 30% increase from the previous quarter, with Amtagvi contributing around $65 million, highlighting strong market demand for this cell-based therapy in advanced melanoma treatment, which is expected to drive significant revenue growth for the company.
- FDA Fast Track Approval: Lifileucel received Fast Track designation from the FDA for previously treated nonsquamous non-small cell lung cancer, with preliminary data showing a 26% objective response rate, which will expedite its anticipated launch in the second half of 2027, further enhancing the company's competitive position in tumor immunotherapy.
- Extremely Bullish Market Sentiment: Retail investor sentiment for Iovance on Stocktwits was extremely bullish, with a 550% surge in message volume over 24 hours, reflecting strong confidence in the company's growth potential, which is likely to drive further stock price increases.
See More
Avaí Bio Initiates Key Cell Bank Project for Therapy Development
- Market Outlook: The regenerative medicine market is projected to reach $578 billion by 2026, with cell therapy alone surpassing $8.2 billion this year, indicating strong growth potential that attracts investor interest.
- Infrastructure Development: Avaí Bio has initiated the creation of a Master Cell Bank (MCB) for the α-Klotho protein in collaboration with Austrianova, ensuring a standardized foundation for future cell therapies, enhancing the feasibility and consistency of product development.
- Scientific Research Support: The α-Klotho protein is extensively studied and linked to reduced risks of Alzheimer's, cardiovascular diseases, and certain cancers, with a significant market potential, as the Alzheimer's market is expected to reach $32.8 billion by 2033.
- Dual-Program Strategy: Avaí Bio's Insulinova platform also utilizes Cell-in-a-Box® technology to target diabetes, showcasing the company's diversified approach in the cell therapy field, thereby enhancing its competitive position in the market.
See More
Avaí Bio Initiates Key Cell Bank Project for Therapy Development
- Market Potential: The regenerative medicine market is projected to reach $578 billion by 2033, with cell therapy alone surpassing $8.2 billion in 2026, indicating a rapid growth trajectory that is attracting significant investment and research resources.
- Infrastructure Importance: Avaí Bio has initiated a Master Cell Bank (MCB) project in collaboration with Austrianova to create a standardized cellular starting material by cloning a single genetically engineered cell into tens of millions of identical copies, ensuring consistency and scalability for future therapy development.
- Clinical Application Outlook: The α-Klotho protein is linked to various age-related diseases, with the Alzheimer's market expected to reach $32.8 billion by 2033, positioning Avaí Bio's research to potentially achieve groundbreaking advancements in these critical health areas.
- Technological Innovation and Market Competitiveness: Avaí Bio's Insulinova platform also leverages Cell-in-a-Box® technology to address diabetes by protecting therapeutic cells, showcasing the company's innovative capabilities and competitive edge in the cell therapy landscape.
See More
How Two Small Biotech Companies Could Pave the Way for Innovative Cancer Therapies
Cancer as a Medical Challenge: Cancer remains a significant challenge for biotechnology firms, with the oncology market projected to surge to $366 billion in the next 80 years, prompting companies to develop targeted treatments for specific cancer types.
Promising Treatments and Market Growth: Several promising cancer treatments have shown incredible potential, leading to significant sales opportunities for biotech firms, particularly those focusing on oncology medicines.
Iovance's Market Performance: Iovance Biotherapeutics has experienced substantial share price growth, driven by its leading cancer drug, which has the potential to generate over $1 billion in U.S. sales, despite facing production challenges.
Immunity Bio's Growth and Challenges: Immunity Bio has seen impressive sales growth for its bladder cancer drug, Anktiva, following regulatory approvals, but it still faces risks and challenges in manufacturing and market competition.
See More
ImmunityBio and Iovance Stock Dynamics Analysis
- Stock Performance Comparison: IBRX's stock has fallen over 7% this week, dropping to $9 on Wednesday, while IOVA's stock has gained nearly 11%, reaching $4.26 on the same day, indicating differing market sentiments that could influence investor decisions.
- Sales Revenue Growth: ImmunityBio generated $113 million in revenue from Anktiva in 2025, up approximately 700% year-over-year, while Iovance reported about $87 million in Q4, exceeding estimates of $81.01 million, demonstrating strong market demand for both companies' therapies.
- Analyst Outlook Assessment: Analyst estimates from Koyfin suggest ImmunityBio has price targets ranging from $9 to $23, with an average target of $14.75 implying a 64% upside from current levels, while Iovance's targets range from $2 to $16, averaging $8.8, indicating a potential 107% upside, reflecting differing market expectations for both firms.
- Clinical Trial Progress: ImmunityBio's Quilt 2.005 trial shows that 85% of patients maintained a complete response at six months with Anktiva and BCG combination therapy, while Iovance's trial in new tumor types shows a 50% response rate, indicating positive advancements in expanding market potential for both companies.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting varying market perspectives and future expectations for these firms.
- ORCL Stock Outlook: Analysts have provided their latest views on ORCL stock for potential buyers, which could influence investor decisions and market sentiment regarding the stock.
- Market Dynamics Overview: The backdrop for these rating changes is a shifting market environment, with analysts evaluating based on the latest financial data and industry trends, indicating a cautious outlook on the overall market.
- Investor Focus: Investors should pay attention to these rating changes as they may impact stock price volatility and investment strategies for the affected companies, particularly in an uncertain economic climate.
See More
Iovance Biotherapeutics Reports Record Q4 Margins and Strong Upside Potential
- Record Quarterly Profit: Iovance reported Q4 revenue of $86.7 million, exceeding analyst expectations of $81 million, with gross margins rising from 43% in Q3 to 50%, demonstrating the effectiveness of operational optimization and indicating potential for future profitability improvements.
- Sales Growth: Total product revenue for Q4 reached approximately $87 million, a 30% increase from the previous quarter, with Amtagvi contributing around $65 million, highlighting strong market demand for this cell-based therapy in advanced melanoma treatment, which is expected to drive significant revenue growth for the company.
- FDA Fast Track Approval: Lifileucel received Fast Track designation from the FDA for previously treated nonsquamous non-small cell lung cancer, with preliminary data showing a 26% objective response rate, which will expedite its anticipated launch in the second half of 2027, further enhancing the company's competitive position in tumor immunotherapy.
- Extremely Bullish Market Sentiment: Retail investor sentiment for Iovance on Stocktwits was extremely bullish, with a 550% surge in message volume over 24 hours, reflecting strong confidence in the company's growth potential, which is likely to drive further stock price increases.
See More
